Goldman Sachs
KYTX icon

Goldman Sachs’s Kyverna Therapeutics KYTX Stock Holding History

Goldman Sachs’s Portfolio KYTX Stock Details KYTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.84M Buy
212,910
+79,380
+59% +$661K ﹤0.01% 4616
2025
Q4 		$1.26M Buy
133,530
+90,398
+210% +$671K ﹤0.01% 4960
2025
Q3 		$259K Sell
43,132
-93,246
-68% -$373K ﹤0.01% 5836
2025
Q2 		$419K Buy
136,378
+31,918
+31% +$78.9K ﹤0.01% 5257
2025
Q1 		$202K Sell
104,460
-9,014
-8% -$26.6K ﹤0.01% 5641
2024
Q4 		$424K Buy
113,474
+33,671
+42% +$161K ﹤0.01% 5333
2024
Q3 		$390K Buy
79,803
+17,513
+28% +$135K ﹤0.01% 5187
2024
Q2 		$467K Buy
+62,290
New +$952K ﹤0.01% 4872

Other funds holding KYTX

GGI
GordonMD Global Investments Beverely Hills, California $144M AUM
GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
IHG
Insight Holdings Group New York $1.42B AUM 41.03% 1-Year Est. Return

Goldman Sachs's KYTX Position: Q1 2026 in Review

Goldman Sachs increased its Kyverna Therapeutics (KYTX) stake by 59% in Q1 2026, buying an estimated $661K and bringing the position to 212,910 shares worth $1.84M. The position accounts for ﹤0.01% of the portfolio, ranked #4616.

Goldman Sachs first reported a position in KYTX in Q2 2024 and has held it in 8 quarters since. 111 funds tracked by Wall St. Rank hold KYTX as of Q1 2026.

  • Goldman Sachs held 212,910 shares of Kyverna Therapeutics worth $1.84M as of Q1 2026.
  • Goldman Sachs bought 79,380 Kyverna Therapeutics shares in Q1 2026, an estimated $661K.
  • Kyverna Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #4616 holding.
  • Goldman Sachs first reported a position in Kyverna Therapeutics in Q2 2024 and has held it in 8 quarters since.
  • 111 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.